Patent intelligence · US
US 12233135
Therapeutic constructs for treating cancer
Therapeutic constructs for treating cancer
Patent details — US 12233135
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 25, 2025
- Expiration
- Feb 20, 2045
- Applicant
- PRECISION MOLECULAR INC.
- Claims
- 20
- CPC classes
- A61K, A61K2039/505, A61K2239/31, A61K2239/38
Quick answer
US 12233135 (Therapeutic constructs for treating cancer) is held by PRECISION MOLECULAR INC.. Status: granted. Granted Feb 25, 2025. Expires Feb 20, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- PRECISION MOLECULAR INC.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K2039/505, A61K2239/31, A61K2239/38, A61K2239/55, A61K38/1774
More from PRECISION MOLECULAR INC.
Related pharmaceutical patents in our USPTO index.
-
US 12419920
Bifidobacterium longum NCIMB 41676
granted -
US 12410418
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
granted -
US 12351839
Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
granted -
US 12344676
Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
granted -
US 12336835
Neuromodulation to target glucose transporter and/or incretin pathways
granted -
US 12232492
Disinfection of bacteriophages products using supercritical carbon dioxide
granted -
US 12180463
Lactobacillus reuteri
granted
Frequently asked questions
What is US patent 12233135?
US 12233135 (Therapeutic constructs for treating cancer) is held by PRECISION MOLECULAR INC.. Status: granted. Granted Feb 25, 2025. Expires Feb 20, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12233135?
PRECISION MOLECULAR INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 158 pharmaceutical patents for this assignee.
When does US 12233135 expire?
Our index shows an expiration date of Feb 20, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.